Metformin in polycystic ovary syndrome
Moll, Etelka

Citation for published version (APA):
Moll, E. (2013). Metformin in polycystic ovary syndrome

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial

Etelka Moll, Patrick M M Bossuyt, Johanna C Korevaar, Cornelis B Lambalk, Fulco van der Veen

BMJ 2006;332(7556):1485-1489
Abstract

Objective To compare the effectiveness of clomifene citrate plus metformin and clomifene citrate plus placebo in women with newly diagnosed polycystic ovary syndrome.

Design Randomised clinical trial.

Setting Multicentre trial in 20 Dutch hospitals.

Participants 228 women with polycystic ovary syndrome.

Interventions Clomifene citrate plus metformin or clomifene citrate plus placebo.

Main outcome measure The primary outcome measure was ovulation. Secondary outcome measures were ongoing pregnancy, spontaneous abortion, and clomifene resistance.

Results 111 women were allocated to clomifene citrate plus metformin (metformin group) and 114 women were allocated to clomifene citrate plus placebo (placebo group). The ovulation rate in the metformin group was 64% compared with 72% in the placebo group, a non-significant difference (risk difference −8%, 95% confidence interval −20% to 4%). There were no significant differences in either rate of ongoing pregnancy (40% v 46%; −6%, −20% to 7%) or rate of spontaneous abortion (12% v 11%; 1%, −7% to 10%). A significantly larger proportion of women in the metformin group discontinued treatment because of side effects (16% v 5%; 11%, 5% to 16%).

Conclusion Metformin is not an effective addition to clomifene citrate as the primary method of inducing ovulation in women with polycystic ovary syndrome.
Introduction

Polycystic ovary syndrome is characterised by any of oligoanovulation, clinical or biochemical hyperandrogenism, and polycystic ovaries. The syndrome affects approximately 4%-9% of women of reproductive age. Women most commonly seek counselling or treatment because of infertility due to chronic anovulation. Insulin resistance accompanied by compensatory hyperinsulinaemia constitutes another major biochemical feature of polycystic ovary syndrome, which leads to early luteinising hormone sensitivity of the follicle and to stimulation of both ovarian and adrenal androgen production.

The first choice drug in women with newly diagnosed polycystic ovary syndrome is the antioestrogen clomifene citrate. Clomifene citrate enhances release of pituitary gonadotrophins, resulting in follicular recruitment. Three quarters of women with polycystic ovary syndrome will ovulate with clomifene citrate. Complications of treatment are rare and usually mild. Patients who do not ovulate on the maximum dose of 150 mg are considered to be clomifene citrate resistant.

Recently, the addition of metformin, an insulin sensitiser, to clomifene citrate has been proposed as an alternative treatment option for women with polycystic ovary syndrome. Insulin sensitisers improve hyperinsulinaemia and hyperandrogenism in these women. One study also showed that metformin regulated menstrual cycles and pregnancies.

Metformin is now the most widely used insulin sensitisier for induction of ovulation in women with polycystic ovary syndrome and may improve ovulation rates when combined with clomifene citrate in clomifene citrate resistant women. This has led to the recommendation to use metformin alone or in combination with clomifene citrate as first line treatment in infertile women with polycystic ovary syndrome.

As clomifene citrate is an effective treatment, however, what are the added benefits of metformin? Two randomised controlled trials have examined this question. One small study found a significant increase in ovulation rates, while a larger study failed to find a significant difference. Sample sizes of both studies were small, performance was not double blinded, and previous treatment of the participants was unclear.

We determined whether a strategy of adding metformin to the standard treatment with clomifene citrate results in a higher ovulation rate, higher pregnancy rate, and
less clomifene citrate resistance in a randomised clinical trial among women with newly diagnosed polycystic ovary syndrome.

**Methods**

**Participants and experimental protocol**

From June 2001 till May 2004 we invited relevant women from 20 Dutch hospitals to participate in the trial. All women had chronic anovulation (menstrual cycle ≥ 35 days, WHO type II, normogonadotropic, normo-oestrogenic, oligoanovulation or anovulation) and polycystic ovaries diagnosed by transvaginal ultrasonography and wanted to conceive.

We defined polycystic ovary syndrome according to current guidelines. We excluded women with other causes of anovulation, age >40 years, and liver, kidney, or heart disease or failure (that is, abnormal results on liver function tests or serum creatinine concentration >95 μmol/l or a history of heart disease or failure) and also those whose partner’s sperm quality indicated male factor subfertility (total motile count < 10x10⁶). Tubal patency was not tested before induction of ovulation.

Women who gave informed consent were randomly allocated to clomifene citrate plus metformin (metformin group) or clomifene citrate plus placebo (placebo group). Randomisation was done in the coordinating centre (AMC, Amsterdam) by using computer generated blocks of four. Merck Santé, France, prepared the containers with the study medication. They determined the final allocation sequence and kept this list until inclusion was finished. The randomisation was stratified per centre, and the centres received blinded, numbered containers with medication. Each participant received the container with the next number in her own hospital.

We tested liver and kidney function before women started taking the study medication. The dose was increased from one to four tablets a day (that is, up to 2000 mg) over a period of seven days. We used this “step up” regimen to limit side effects. Patients continued to take the study medication until they had a positive pregnancy test or six ovulatory cycles or developed clomifene citrate resistance, whichever came first.

Women took metformin or placebo for one month, to allow metformin enough time to have a sufficient insulin sensitising effect. If no spontaneous menstruation occurred and the pregnancy test was negative one month after the study medication
was started, we induced menstruation with dydrogesterone 10 mg three times a day for ten days. From the third or fifth day until the seventh or ninth day after (spontaneous or induced) menstruation, women took 50 mg clomifene citrate a day. If ovulation did not occur with this dose, it was increased with steps of 50 mg to a maximum of 150 mg a day in the next cycles. Ovulation was detected either with a biphasic basal temperature curve, a follicle with a diameter ≥16 mm on transvaginal ultrasonography, or progesterone ≥14 nmol/l in the second half of a menstrual cycle, or pregnancy. If a woman ovulated, she continued taking the same dose of clomifene citrate until an end point was reached.

If women had an ovulatory cycle with a certain dose of clomifene citrate followed by a cycle without ovulation at the same dose, they were classified as temporarily ovulatory. These women entered the next cycle with a higher dose of clomifene citrate.

**Statistical analysis**

The primary outcome measure was ovulation. Secondary outcome measures were ongoing pregnancy, spontaneous abortion, and clomifene resistance. We compared the cumulative rates of ovulation as well as other rates and proportions between groups using relative rates, rates differences, and \( \chi^2 \) test statistics using SPSS 11.5.1.

With an expected rate of ovulation of 75% in the placebo group,\(^{10,17}\) we needed 200 women to show an absolute increase of 15% in ovulation rate, with a power of at least 80% using a two sided \( \chi^2 \) test with a 5% significance level.

**Results**

We screened 228 women for eligibility. Three had to be excluded: two had type 2 diabetes and one had raised liver enzyme activity. Baseline characteristics were similar in the two groups apart from the mean total motile sperm count in partners (table 1).

In the 111 women allocated to metformin, six became pregnant and five dropped out before they started taking the study medication (fig 1). Eighty women received 50 mg clomifene citrate, of whom 44 went on to take 100 mg clomifene citrate, and 17 eventually took 150 mg. Twelve women developed resistance to clomifene citrate.
In the 114 women allocated to the placebo group, four became pregnant and nine dropped out before they started taking the study medication. Ninety two women received 50 mg clomifene citrate, of whom 54 went on to take 100 mg clomifene citrate, and 23 eventually took 150 mg. Thirteen women developed resistance. In both groups none of the cycles was cancelled and no one developed ovarian hyperstimulation syndrome.

Cumulative rates of ovulation were slightly lower in the metformin group, but this difference was not significant, nor were differences in cumulative pregnancy and spontaneous abortion rates (table 2). There were no significant differences between the two groups when we analysed the data by clomifene citrate dose (table 3).

In the metformin group, 28 women stopped treatment before reaching an end point. Eighteen stopped because of side effects, 10 because of other or unspecified reasons.

In the placebo group, 21 women stopped treatment before reaching an end point. Six stopped because of side effects, 10 because of other or unspecified reasons, and five had a concomitant disease that prevented continuation of the study.

There was a significant difference between the metformin and placebo group in the discontinuation because of side effects (16% v 5%; risk difference 11%, 95% confidence interval 5% to 16%).

As 63 women discontinued study medication, 78 and 84 remained for the per protocol analyses. The results in those who did not withdraw showed no benefit with metformin (table 4).

By the end of follow-up there were 21 live births without complications in the metformin group, 13 spontaneous abortions and 14 ongoing singleton pregnancies. There were three premature deliveries (gestational age 36+0, 33+1, and 17+5 weeks). The last pregnancy concerned triplets; none of whom survived. One woman developed gestational diabetes, but she delivered without complications. Four patients developed hypertension; three delivered without complications, one had a child with Kartagener’s syndrome and hypospadias. One woman developed pre-eclampsia and delivered prematurely (32+6 weeks). The child had anal atresia.

In the placebo group there were 30 live births without complications, 1 live twin birth without complications, 12 spontaneous abortions, 9 ongoing singleton pregnancies, and two ongoing twin pregnancies. There was one case of intra uterine growth retardation and two premature deliveries (34+1 and 18+0 weeks). The last delivery
concerned an anencephalic child that did not survive. Two women developed
gestational diabetes and two developed hypertension, all four delivered without
further complications. Three patients developed preeclampsia; two delivered without
complications, one delivered prematurely (36+0 weeks).

There were no significant differences in complications of pregnancy,
gestational age, complications of delivery, birth weights, or congenital malformations
between the two groups. The power for these comparisons, however, was low.

Discussion

In the treatment of women with polycystic ovary syndrome who want to get
pregnant we could not find any benefit of adding metformin to the standard treatment
with clomifene citrate. We found no significant differences in outcome and can
exclude any substantial improvement in rates of ovulation and ongoing pregnancy.
Significantly more women in the metformin group discontinued treatment because of
side effects.

Patients—We included women with polycystic ovary syndrome, defined according
to the 2003 consensus,\textsuperscript{1} who had never used clomifene citrate before and were
seeking treatment for their fertility problems for the first time. We evaluated eligibility
irrespective of their body mass index. By using these criteria our study group reflects
the largest group of women with polycystic ovary syndrome a fertility clinic will see
and treat.

Ovulation—Metformin monotherapy induces ovulation through its insulin
sensitizing effect. In our study, however, we failed to find an increase in ovulation
rate of combined therapy compared with clomifene citrate alone. The effects of
metformin on ovulation may not be sufficiently strong to improve on the already high
ovulation rates with clomifene citrate in these women. This theory is strengthened by
the fact that insulin resistance did not improve substantially. It is possible that those
women who ovulate on metformin monotherapy would also ovulate on clomifene
citrate monotherapy, explaining the absence of an added effect. Our participants
were less obese than women in previous studies. Our group represents a normal
range of women with polycystic ovary syndrome. Around 35-60% of women with
polycystic ovary syndrome are overweight. Nevertheless, lean women are less likely
to benefit from insulin sensitizers because they are less insulin resistant.
**Dropouts**—The number of dropouts in the metformin group was relatively high in the first month of use. Previous studies have shown that it is not uncommon for patients to experience side effects but that these wear off after a certain time.\(^\text{18}\) There were no differences in baseline characteristics between the women who dropped out and those who completed the study (data not shown). Previous studies have not reported any dropouts.\(^\text{14;15}\)

**Comparison**—Our findings confirm those of El-Biely and Habba\(^\text{15}\) but conflicts with those of Nestler et al.\(^\text{14}\) The mean body mass index was lower in our participants (28 \(\text{v} 32\)) and more were hyperandrogenic (free androgen index 12 \(\text{v} 3\)) than in the Nestler study. Our participants were more representative of women with polycystic ovary syndrome in Europe.

**Schedule**—Previous studies have evaluated one menstrual cycle only\(^\text{14}\) or included patients for six months,\(^\text{15}\) whereas our study evaluated six ovulations or lasted until clomifene citrate resistance developed. We think this is a more realistic strategy from a clinical point of view. The downside of this strategy may have been the unexpectedly high rate of women dropping out. As we did not account for this in the power calculation, the power to detect smaller differences has been attenuated. Nevertheless, ovulation rates were lower in the metformin group, and the confidence intervals exclude substantial gains in ovulation and pregnancy rates from adding metformin.

**Spontaneous abortion**—Some authors have reported that metformin can decrease the rate of spontaneous abortion in women with polycystic ovary syndrome.\(^\text{19-21}\) In our study the rate was similar in both groups and comparable with the rate in the general population.\(^\text{22-24}\) There was no evidence of any protective effect against spontaneous abortion in the metformin group, though this study was not powered for this question. Women had to discontinue their medication as soon as they had a positive pregnancy test as the safety and benefit of using metformin during pregnancy have not yet been proved. This might partially explain why the proportion of miscarriages was equal between the groups.

**Conclusion**

Based on the results of this trial, we cannot exclude the possibility that addition of metformin may lead to an increase in the ovulation rate of up to 5%, though whether such a small difference is clinically relevant is doubtful. Though metformin seems to be a relatively safe medication, it is associated with a high incidence of side effects.\(^\text{18}\)
We conclude that metformin should not be added to clomifene citrate as primary method for induction of ovulation in women with polycystic ovary syndrome.

Acknowledgements
We thank the following participants for including and treating patients in this study: R E Bernardus (Ziekenhuis Gooi Noord, Blaricum); H E Bobeck (Rode Kruis Ziekenhuis, Beverwijk); D D M Braat, W N P Willemsen (Universitair Medisch Centrum, Sint Radboud, Nijmegen); J W Briët (Deventer Ziekenhuis, Deventer); J Dawson, I van der Laar (Sint Lucas Ziekenhuis, Amsterdam); H J H M van Dessel, T J G Griffioen (Twee Steden Ziekenhuis, Tilburg); J P R Doornbos (Zaans Medisch Centrum, De Heel, Zaandam); J J Duvekot, H Versendaal (Medisch Centrum Rijnmond Zuid, Rotterdam); M H Emanuel (Spaarne Ziekenhuis, Haarlem); P A Flierman, H Verhoeve (Onze Lieve Vrouwe Gasthuis, Amsterdam); D A Gietelink, A M Bongers (Amphia Ziekenhuis, Breda); M H A van Hooff (Sint Franciscus Gasthuis, Rotterdam); P W H Houben (Gemini Ziekenhuis, Den Helder); Y M van Kasteren, R Weselius (Medisch Centrum Alkmaar, Alkmaar); C B Lambalk, J J M L Dekker (Vrije Universiteit Medisch Centrum, Amsterdam); S van der Meer, C van Bolhuis (Medisch Centrum Haaglanden, Den Haag); A W J Omtzigt, P van Berlo (Flevziekenhuis, Almere); CN M Renckens (Westfries Gasthuis, Hoorn); E Scheenjes (Ziekenhuis Gelderse Vallei, Ede); M A H M Wiegerinck, P Maas-van Son, B W Mol (Maxima Medisch Centrum, Veldhoven). We thank Nathalie Cugnardey, Merck Santé, France, and Louis LM van de Ven, Merck, Netherlands.
References


Figure 1. Overview of the clinical trial. Women shown as receiving 50 or 100mg clomifene citrate received one to six cycles at the noted dose. Ovulatory=women with six ovulatory cycles in total, without pregnancy; temporarily ovulatory=women who ovulated on a certain dose of clomifene citrate at one point in the study and were anovulatory on the same dose at another point in the study. They were treated with a higher dose in the next cycle.
Table 1. Baseline characteristics of women in study according to allocation to clomifene citrate plus metformin or clomifene citrate plus placebo. Figures are numbers (percentages) of women unless stated otherwise.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Clomifene citrate and metformin n=111</th>
<th>Clomifene citrate and placebo n=114</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) age (years)</td>
<td>27.9 (3.7)</td>
<td>28.4 (4.7)</td>
</tr>
<tr>
<td>Parity:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nulliparous</td>
<td>89 (80%)</td>
<td>95 (84%)</td>
</tr>
<tr>
<td>Multiparous</td>
<td>22 (20%)</td>
<td>18 (16%)</td>
</tr>
<tr>
<td>Mean (SD) duration of trying to conceive (years)</td>
<td>1.6 (1.2)</td>
<td>1.3 (1.1)</td>
</tr>
<tr>
<td>Mean(SD) BMI (kg/m²)</td>
<td>28.5 (7.1)</td>
<td>27.8 (6.7)</td>
</tr>
<tr>
<td>BMI ≥ 25</td>
<td>59/104 (57%)</td>
<td>60/109 (55%)</td>
</tr>
<tr>
<td>Mean (SD) waist:hip ratio</td>
<td>0.82 (0.1)</td>
<td>0.83 (0.1)</td>
</tr>
<tr>
<td>Mean (SD) LH:FSH ratio</td>
<td>1.92 (1.27)</td>
<td>2.13 (1.37)</td>
</tr>
<tr>
<td>Mean (SD) testosterone (nmol/l)</td>
<td>3.49 (3.68)</td>
<td>3.55 (3.54)</td>
</tr>
<tr>
<td>Testosterone concentration ≥ 4 nmol/l</td>
<td>37 (33%)</td>
<td>35 (31%)</td>
</tr>
<tr>
<td>Mean (SD) free androgen index</td>
<td>12.90 (17.95)</td>
<td>11.74 (11.89)</td>
</tr>
<tr>
<td>Free androgen index ≥ 8</td>
<td>33/70 (47%)</td>
<td>35/69 (51%)</td>
</tr>
<tr>
<td>Mean (SD) volume of ovaries (ml)</td>
<td>9.1 (6.1)</td>
<td>10.1 (4.9)</td>
</tr>
<tr>
<td>Ovary volume ≥ 10ml</td>
<td>19/70 (27%)</td>
<td>26/65 (40%)</td>
</tr>
<tr>
<td>Mean (SD) total motile sperm count (x10⁸)</td>
<td>134 (223)</td>
<td>222 (370)</td>
</tr>
<tr>
<td>Homeostasis Model Assessment (HOMA)</td>
<td>4.6 (8.3)</td>
<td>3.8 (4.6)</td>
</tr>
</tbody>
</table>

BMI=body mass index; LH:FSH ratio=luteinising hormone:follicle stimulating hormone.
Table 2. Rates of ovulation, pregnancy and spontaneous abortion rates. Figures are numbers (percentages) of women in each group.

<table>
<thead>
<tr>
<th></th>
<th>Clomifene citrate + metformin (n=111)</th>
<th>Clomifene citrate + placebo (n=114)</th>
<th>Risk difference % (95% CI)</th>
<th>Relative risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovulation</td>
<td>71 (64)</td>
<td>82 (72)</td>
<td>-8 (-20 to 4)</td>
<td>0.89 (0.7 to 1.1)</td>
</tr>
<tr>
<td>Ongoing pregnancy</td>
<td>44 (40)</td>
<td>52 (46)</td>
<td>-6 (-20 to 7)</td>
<td>0.87 (0.6 to 1.2)</td>
</tr>
<tr>
<td>Spontaneous abortion</td>
<td>13 (12)</td>
<td>12 (11)</td>
<td>1 (-7 to 10)</td>
<td>1.11 (0.5 to 2.3)</td>
</tr>
</tbody>
</table>

Table 3. Ovulation per dose of clomifene citrate. Figures are numbers (percentages) of women who ovulated out of the total number of women.

<table>
<thead>
<tr>
<th>Dose</th>
<th>Clomifene citrate + metformin</th>
<th>Clomifene citrate + placebo</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>50mg</td>
<td>49/80 (61)</td>
<td>50/92 (54)</td>
<td>0.36</td>
</tr>
<tr>
<td>100mg</td>
<td>27/44 (61)</td>
<td>35/53 (66)</td>
<td>0.63</td>
</tr>
<tr>
<td>150mg</td>
<td>8/17 (47)</td>
<td>13/23 (57)</td>
<td>0.55</td>
</tr>
</tbody>
</table>

Table 4. Rates of ovulation, pregnancy and spontaneous abortion rates (per protocol analysis). Figures are numbers (percentages) of women

<table>
<thead>
<tr>
<th></th>
<th>Clomifene citrate + metformin (n=78 )</th>
<th>Clomifene citrate + placebo (n=84)</th>
<th>Risk difference % (95% CI)</th>
<th>Relative risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovulation</td>
<td>61 (78)</td>
<td>68 (81)</td>
<td>-3 (-15 to 10)</td>
<td>0.97 (0.8 to 1.1)</td>
</tr>
<tr>
<td>Ongoing pregnancy</td>
<td>44 (56)</td>
<td>51 (61)</td>
<td>-4 (-19 to 11)</td>
<td>0.93 (0.7 to 1.2)</td>
</tr>
<tr>
<td>Spontaneous abortion</td>
<td>13 (17)</td>
<td>12 (14)</td>
<td>2 (-9 to 14)</td>
<td>1.17 (0.6 to 2.4)</td>
</tr>
</tbody>
</table>